Literature DB >> 12442270

Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.

Nayanta Sodha, Richard S Houlston, Sarah Bullock, Martin A Yuille, Carol Chu, Gwen Turner, Rosalind A Eeles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12442270     DOI： 10.1002/humu.10136

Source DB:  PubMed          Journal:  Hum Mutat        ISSN： 1059-7794            Impact factor:   4.878


× No keyword cloud information.
  12 in total

Review 1.  Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management.

Authors:  R N Moule; S G Jhavar; R A Eeles
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

2.  Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation.

Authors:  Navid Sadri; Lea F Surrey; Douglas L Fraker; Paul J Zhang
Journal:  Virchows Arch       Date:  2014-03-05       Impact factor: 4.064

3.  Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias.

Authors:  El Mustapha Bahassi; Susan B Robbins; Moying Yin; Gregory P Boivin; Raoul Kuiper; Harry van Steeg; Peter J Stambrook
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-21       Impact factor: 11.205

4.  A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.

Authors:  Deborah Thompson; Sheila Seal; Mieke Schutte; Lesley McGuffog; Rita Barfoot; Anthony Renwick; Rosalind Eeles; Nayanta Sodha; Richard Houlston; Susan Shanley; Jan Klijn; Marijke Wasielewski; Jenny Chang-Claude; P Andrew Futreal; Barbara L Weber; Katherine L Nathanson; Michael Stratton; Hanne Meijers-Heijboer; Nazneen Rahman; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12       Impact factor: 4.254

5.  CHEK2 contribution to hereditary breast cancer in non-BRCA families.

Authors:  Alexis Desrichard; Yannick Bidet; Nancy Uhrhammer; Yves-Jean Bignon
Journal:  Breast Cancer Res       Date:  2011-11-24       Impact factor: 6.466

6.  Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs.

Authors:  Yoji Kukita; Jiro Okami; Noriko Yoneda-Kato; Ikuko Nakamae; Takeshi Kawabata; Masahiko Higashiyama; Junya Kato; Ken Kodama; Kikuya Kato
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

7.  The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype.

Authors:  Marielle W G Ruijs; Annegien Broeks; Fred H Menko; Margreet G E M Ausems; Anja Wagner; Rogier Oldenburg; Hanne Meijers-Heijboer; Laura J van't Veer; Senno Verhoef
Journal:  Hered Cancer Clin Pract       Date:  2009-02-17       Impact factor: 2.857

8.  CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer.

Authors:  Sara Margolin; Hans Eiberg; Annika Lindblom; Marie Luise Bisgaard
Journal:  BMC Cancer       Date:  2007-08-17       Impact factor: 4.430

9.  CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer.

Authors:  Peilin Zhang; Jie Wang; Weiyi Gao; Bao-Zhu Yuan; John Rogers; Eddie Reed
Journal:  Mol Cancer       Date:  2004-05-04       Impact factor: 27.401

10.  Case report of a Li-Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2.

Authors:  Xuehan Zhuang; Yongping Li; Hongzhi Cao; Ting Wang; Jianghao Chen; Jiayun Liu; Liya Lin; Rui Ye; Xinyang Li; Shuang Liu; Weiyang Li; Yonggang Lv; Juliang Zhang; Chenyang He; Xun Xu; Zhen Wang; Chen Huang; Xiao Liu; Ling Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.